NCT07117864View on ClinicalTrials.gov

Exploration of the Safety and Efficacy of T-DXd Concurrent With Brain Radiotherapy in Patients With Brain Metastases HER2-positive/HER2-low Advanced Breast Cancer

NARecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 1, 2025

Primary Completion Date

July 31, 2026

Study Completion Date

July 31, 2026

Conditions

Breast Cancer

Interventions

COMBINATION_PRODUCT

T-DXd concurrent brain radiotherapy

T-DXd：5.4mg/kg ivgtt Q3w SRT/WBRT

Trial Locations (1)

Unknown

RECRUITING

Cancer Hospital Chinese Academy of Medical Sciences, Beijing

All Listed Sponsors

lead

QIAO LI

OTHER

NCT07117864 - Exploration of the Safety and Efficacy of T-DXd Concurrent With Brain Radiotherapy in Patients With Brain Metastases HER2-positive/HER2-low Advanced Breast Cancer | Biotech Hunter | Biotech Hunter